Crystalline Dexamethasone Dimers for Carrier-Free Controlled Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing sustained drug delivery systems face challenges such as drug degradation, uncontrolled release, burst release, low encapsulation efficiency, and formulation complexity, particularly for locally administered dexamethasone, which can cause unwanted side effects.
Innovation Solution
Development of crystalline forms of dexamethasone prodrug dimers that form pharmaceutical compositions in a glassy state, allowing for controlled release through surface erosion without carriers or excipients, ensuring uniform and sustained drug release over extended periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If sustained drug delivery systems are used to maintain effective dexamethasone concentrations over extended periods, then the duration of action is improved, but drug degradation and uncontrolled release occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of dexamethasone to create prodrug dimers with altered physical and chemical properties. The prodrug dimers exhibit different solubility, stability, and crystallization characteristics compared to parent dexamethasone, enabling controlled release without degradation. Specifically, the dimerization process changes molecular weight, polarity, and crystalline packing, which directly address the contradiction between extended duration and drug stability.
Solution Approach 2:
The patent utilizes phase transitions by exploiting the crystallization behavior of prodrug dimers from melt or solution states. The controlled crystallization process forms stable solid dosage forms with defined release characteristics. The phase transition from liquid melt to crystalline solid during manufacturing creates a stable matrix that prevents drug degradation while enabling sustained release over time, directly resolving the contradiction between duration and reliability.
2Duration of action of moving object
If sustained drug delivery systems with carriers or excipients are used, then the duration of action is improved, but formulation complexity increases
Solution Approach 1:
The patent applies the extraction principle by removing carriers and excipients from the formulation entirely. The prodrug dimers themselves form the therapeutic matrix through their inherent ability to crystallize from melt or solution, eliminating the need for separate carrier materials. This simplification directly addresses the contradiction by maintaining extended duration of action while reducing formulation complexity to essentially pure prodrug dimer compositions.
Solution Approach 2:
The prodrug dimers serve multiple functions simultaneously: they are the therapeutic agent, the structural matrix, and the controlled-release mechanism. The dual functionality of the prodrug dimer molecule eliminates the need for separate carrier and excipient components, directly resolving the contradiction between extended duration and formulation simplicity by making the drug substance itself perform all necessary functions.
3Duration of action of moving object
If conventional dexamethasone formulations are used for local administration, then the duration of action is improved, but unwanted side effects increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical parameters of dexamethasone through prodrug dimerization. The altered molecular structure changes the drug's release kinetics, solubility, and tissue interaction properties. These parameter changes enable sustained local concentrations to be maintained while reducing peak concentrations that cause side effects, directly addressing the contradiction between duration and harm reduction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms provide stable, controlled drug release profiles with minimal side effects, maintaining effective dexamethasone concentrations for days to months or years, and can be administered via various routes including intraarticular injection.
Implementation Method 1
the crystalline forms can be included in pharmaceutical compositions formulated for administration to a subject (e.g., oral dosage forms or injectable dosage forms)
Implementation Method 2
characterized by a powder X-ray diffraction (PXRD) diffractogram (Cu, λ=1.54060) including peaks expressed in degrees 2θ (±0.2°) at: 3.8°, 7.6°, and 12.1°
Data Source
AI summary
The disclosure features polymorphs of a prodrug dimer of dexamethasone linked at the 21-C and 21′-C carbons via a carbonate-triethylene glycol-carbonate linker. Also disclosed are pharmaceutical compositions and articles comprising said polymorphs, and the use thereof in the treatment of a disease or condition, e.g. via the extended or controlled release of dexamethasone from said articles.